Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD133, also known as Prominin-1, is a pentaspan transmembrane glycoprotein primarily expressed on primitive cell populations such as hematopoietic, neural, and endothelial stem and progenitor cells. While its precise physiological function remains unclear, it plays a role in maintaining plasma membrane architecture and acts as a marker for cancer stem-like cell populations in various solid tumors. Its expression correlates with tumor progression and metastasis and interacts with intracellular signaling pathways such as Wnt and PI3K/Akt. Mutations in PROM1/CD133 are associated with degenerative retinal diseases such as retinitis pigmentosa and Stargardt disease.
Unknown, but involved in signaling pathways such as Wnt/β-catenin and PI3K/Akt.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD133 antigen (CD133).